Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Ratio (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Equity Ratio for 16 consecutive years, with 0.64 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 18.67% to 0.64 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.64, a 18.67% decrease, with the full-year FY2024 number at 0.78, up 555.56% from a year prior.
  • Equity Ratio was 0.64 for Q3 2025 at Gyre Therapeutics, down from 0.85 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 8.56 in Q3 2023 to a low of 0.12 in Q4 2023.
  • A 5-year average of 1.65 and a median of 0.84 in 2021 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: soared 804.18% in 2023, then crashed 90.82% in 2024.
  • Gyre Therapeutics' Equity Ratio stood at 1.07 in 2021, then fell by 20.24% to 0.85 in 2022, then plummeted by 85.95% to 0.12 in 2023, then surged by 555.56% to 0.78 in 2024, then dropped by 18.51% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Equity Ratio are 0.64 (Q3 2025), 0.85 (Q2 2025), and 0.8 (Q1 2025).